Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update

Satellos Bioscience said its SAT-3247 showed encouraging early signs in a six-month update from the ongoing TRAILHEAD study in four adult Duchenne muscular dystrophy patients, with stability or improvement across several measures.

The interim data showed a clean safety profile , with only mild or moderate adverse events, no serious adverse events, no discontinuations, and full treatment compliance.

Key efficacy signals included improved muscle fat fraction , better upper-limb activity, stable strength, lower creatine kinase levels, and reduced fatigue, while the company expects 12-month TRAILHEAD data and initial BASECAMP readouts in the fourth quarter.

Satellos Bioscience NASDAQ: MSLE said interim six-month data from its ongoing TRAILHEAD study showed encouraging safety and efficacy signals for SAT-3247, its investigational therapy for Duchenne muscular dystrophy, in a small cohort of adult participants.

The company reported results from four adults with Duchenne muscular dystrophy, or DMD, ages 21 to 28, who had previously completed the 28-day CL-101 study and then enrolled in TRAILHEAD.

Chief Medical Officer Dr. Wildon Farwell said the data through day 140 of TRAILHEAD, representing roughly six months of overall exposure across CL-101 and TRAILHEAD, showed stability or improvement across several measures, including muscle fat fraction, upper limb activity, strength, biomarkers and patient-reported fatigue.

Farwell emphasized that the study remains ongoing and that SAT-3247 is not approved in any country or region.

The company expects to report 12-month data from the first four TRAILHEAD participants in the fourth quarter.

Safety Profile Remained Clean in Interim Data In TRAILHEAD, participants received 60 milligrams of...